Daniel Castellano

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801).

R. Salazar, A. Abad, I. Durán, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

C. Porta, M. Gore, L. Crinò, 2015, British Journal of Cancer.

EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees

S. Culine, A. Horwich, J. Witjes, 2020 .

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

E. Van Cutsem, E. Raymond, A. Vinik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

Y. Bang, E. Van Cutsem, E. Raymond, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

J. Carles, M. Margelí, J. Aparicio, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.